Q3 Review: Editor’s Picks Of Scrip's Top Stories
COVID-19 Product Development, Gene Therapy Setbacks And Record-Breaking IPOs
Executive Summary
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
You may also be interested in...
Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.
Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration
INFOGRAPHIC: A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.
Top 10 Best-Selling Drugs Of 2020
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.